CLINICAL TRIAL: RITUXIMAB IN SUBJECTS WITH ISN/RPS CLASS III OR IV LUPUS NEPHRIT

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to investigate the safety and efficacy of rituximab in combination with mycophenolate mofetil (MMF) compared with placebo in combination with MMF in the treatment of lupus nephritis. Rituximab is a monoclonal antibody, which is a protein that helps protect the body against foreign materials. It decreases some types of B-cells in the body which may be important in inflammation. Rituximab has been used in a small number of patient with lupus nephritis, and this study is designed to further evaluate whether rituximab would reduce the signs and symptoms of lupus and lupus nephritis.